Antihypertensive drug use and the risk of ovarian cancer death among Finnish ovarian cancer patients : a nationwide cohort study
Santala, Eerik E.E.; Artama, Miia; Pukkala, Eero; Visvanathan, Kala; Staff, Synnöve; Murtola, Teemu J. (2021)
Santala, Eerik E.E.
Artama, Miia
Pukkala, Eero
Visvanathan, Kala
Staff, Synnöve
Murtola, Teemu J.
2021
2087
Julkaisun pysyvä osoite on
https://urn.fi/URN:NBN:fi:tuni-202105275519
https://urn.fi/URN:NBN:fi:tuni-202105275519
Kuvaus
Peer reviewed
Tiivistelmä
Ovarian cancer (OC) has a poor prognosis. Hypertension may be a prognostic factor for OC, but it is unclear whether antihypertensive (anti-HT) drug use of modifies OC prognosis. We performed a population-based analysis assessing the effect of anti-HT drug use on OC mortality. A cohort of 12,122 women identified from the Finnish Cancer Registry with OC in 1995–2013 was combined with information on their anti-HT drug use during the same time period. Use of each anti-HT drug was analysed as a time-dependent variable. Analyses were run for five, ten and full follow-up (19-year) mortality with cardiovascular morbidity risk evaluated in competing risk analysis. No anti-HT drug group was associated with OC survival within five years after OC diagnosis. At ten years, a dose-dependent association was observed between pre-diagnostic ACE-inhibitor use and improved OC survival. With full follow-up, post-diagnostic high-intensity use associated with reduced OC death risk for multiple anti-HT drug groups. In competing risk analysis, only the post-diagnostic use of ACE-inhibitors associated with increased OC survival. Anti-HT drugs were not associated with survival benefits within five years after OC diagnosis. ACE-inhibitors may confer survival benefits in women with OC, but further confirmatory studies are needed.
Kokoelmat
- TUNICRIS-julkaisut [16929]